Taiga Biotechnologies

Biotechnology, Life Science, Therapeutics
Founded in 1/1/06
Aurora, Colorado, United States
http://taigabiotech.com
For Profit

About Taiga Biotechnologies

Taiga Biotechnologies is a clinical-stage company focused on harnessing the immune system to fight infectious disease and cancer. The company's Bone Marrow Engraftment Enhancer (BMEE) program is developing a first-line product, TBX-1400, to enhance the engraftment of hematopoietic stem and progenitor cells during an allogeneic hematopoietic stem cell transplant (HSCT). Taiga Biotechnologies lead Cell-Based Immunotherapy product candidate, TBX-3400, uses a patient’s own immune cells to help fight against cancer and infectious disease. TBX-3400 is an autologous cell product made from peripheral blood mononuclear cells that are treated ex vivo with our fusion protein and then delivered intravenously back to the patient the following day. They developing technologies to generate red blood cells in the laboratory for clinical applications and products to improve the utility of red blood cell products.

Company Metrics

  • Employees: 10-Jan
  • Monthly Visits: None
  • Tech Stack: 18 active products

Financial Information

  • Estimated Revenue: $1M to $10M
  • Total Funding: 52259302 USD
  • Last Funding: 13957000 USD (Debt Financing)
  • Funding Status:

Technology Stack

Taiga Biotechnologies actively uses 18 products in their tech stack.

Market Presence

Industries: Biotechnology, Life Science, Therapeutics

Headquarters: Aurora, Colorado, United States